Exploring the Link Between Neurospirochetosis, Lyme Disease (Borrelia burgdorferi) & Multiple Sclerosis (MS)

Start here#

If you look, you find it. For over a century, pathologists have reported spirochetes in brains, and then the findings were left behind rather than followed up. Lyme's agent, Borrelia burgdorferi, doesn't stop at joints; it crosses endothelium, enters the CNS, and leaves footprints that overlap MS. Tests miss a subset of cases. What that subset means is the contested question. Patients live it either way.

What this gives you:

• What autopsies and stains actually show about Borrelia in brains
• Why "negative" tests don't mean nothing's there
• How transmission likely extends beyond ticks
• What you can do now: remove food triggers, stack antimutagens, and track your response

Neurospirochetosis & MS#

The proposal: that MS is, at least in some patients, neurospirochetosis driven by Borrelia burgdorferi sensu lato. It is an old hypothesis with a real evidence base, and it is not accepted neurology. Across at least ten countries and more than a century of reports, autopsy and case series (1911 → present) describe spirochetes in the brains of deceased MS patients, largely from a small number of research groups and largely in hypothesis-tier venues (Miklossy 2011; MacDonald 2006). Standard testing in living patients misses a subset of cases, and some MS patients test positive on expanded panels. That is the observation layer. Causation, prevalence, and treatment response are unestablished.

The case-literature record:

• Living Borrelia detected in MS brains.
• Borrelia burgdorferi found in ~25% of Alzheimer's cases, far more than in controls.
• Periodontal Treponemas observed in >90% of Alzheimer's brains.

The thread through it all: neurospirochetosis is visible in this literature when you look at it. What the literature cannot yet tell you is how often that finding appears in unselected MS brains, or whether eradicating it changes the disease. Both are open questions.

The contested literature, in its own words#

From the paper itself (a hypothesis-tier venue, Med Hypotheses):

"Microscopic images of cystic spirochetes are difficult to ignore… endowments have nearly expunged all cystic spirochetal image data from current textbooks… Variously sized cystic spirochetal profiles within diseased nerve cells explain: Lewy bodies, Pick bodies, ALS spherical bodies, Alzheimer plaques… spirochetes are hiding in plain sight."

https://doi.org/10.1016/j.mehy.2006.02.035

Why "cured" is contested: persistence biology#

The short-course position rests on a simple premise: that Borrelia is an easy target for antibiotics. The persistence literature says the premise is incomplete. The bacterium is a persistence specialist, and that biology is published, not fringe. The live dispute is over whether persisting organisms explain ongoing symptoms in treated patients.

The persistence toolkit: how Borrelia survives#

Animal and in-vitro work documented spirochetes surviving in tissues after standard antibiotic courses (Embers 2012). Here is the survival toolkit that literature describes:

Round Body/Cyst Forms (The Dormant Enemy) When Borrelia faces pressure (antibiotics, pH shifts, temperature changes), it doesn't die. It shape-shifts into dormant round bodies (cysts) that antibiotics can't touch. These forms can survive for months, then revert back to motile spirochetes when conditions improve. The cyst in your cover image? That's not a dying bacterium. That's a bunker.

HISTORICAL NOTE: MacDonald's paper argues that cystic-form imagery dropped out of textbooks ("expunged", in his word). Whether that reflects deliberate removal or changing fashion in microbiology teaching is his interpretation, published in a hypothesis-tier venue; the drop-out itself is his account, not a documented history.

Biofilm Communities (The Fortress) Eva Sapi's 2012 study proved Borrelia forms protective biofilm-like aggregates encased in a matrix. These structures:

• Block antibiotic penetration
• Shield bacteria from immune detection
• Allow gradual re-seeding of infection

Intracellular Hiding (The Trojan Horse) Fibroblasts. Endothelial cells. Neural cells. Borrelia invades them all without killing the host cell. From inside, it's protected from both antibodies and most antibiotics. This is why the pathogen can persist for decades in tissues, while blood tests come back "negative."

Persister Cells (The Zombie State) A subpopulation enters slow-growing dormancy, highly tolerant to antibiotics that target active metabolism. Zhang's Johns Hopkins lab proved these persister cells survive standard Lyme antibiotics better than actively dividing spirochetes.

THE BOTTOM LINE: Standard regimens were designed and trialled against acute infection. Persistence after treatment is documented in animal models; whether it drives human symptoms is the contested question, and the retreatment trials are mixed (see the counter-evidence section).

The Rash That Wasn't There: Built-In Diagnostic Failure#

The "bull's-eye" erythema migrans (EM) rash is the diagnostic hallmark, or so we're told. Here's the reality the CDC doesn't emphasize:

• Bull's-eye pattern = minority (~20–30% of cases)
• Most EM rashes are solid red, expanding without central clearing
• 20–30% of confirmed cases have no recalled rash at all
• Common misdiagnoses: spider bite, cellulitis, ringworm, allergic reaction

This isn't an unfortunate coincidence. When your "hallmark sign" is absent in most cases, under-detection follows from the sign itself, whatever the guidelines say. By the time the rash disappears or never appears, the bacteria have already disseminated. The testing window closes before most patients even seek care.

THE DIAGNOSTIC GAP: When the classical sign is absent in most cases, under-detection is structural, not incidental. No bull's-eye = lower suspicion = delayed or missed diagnosis, whichever pathogen is involved.

Lyme vs MS#

The MS-as-neurospirochetosis hypothesis has a century of case-level support and no controlled confirmation. The same research groups produced most of it; that is a limitation, and also how a neglected question stays alive. What the case literature reports:

Highlights (case reports and series unless stated):

• Mother-to-child transmission of Borrelia across the womb
• B. burgdorferi + B. miyamotoi with amyloid plaques in AD brains
• Borrelia in Lewy body dementia
• Nematode worms reported in CSF of MS patients
• Borrelia signals in glioblastoma multiforme
• B. mayonii and B. burgdorferi found in human testicles
• Borreliosis is a family, not one bug/one symptom, B. miyamotoi sits alongside B. burgdorferi in brains → eradicate together

These observations motivate the hypothesis. None of them establishes that Lyme causes MS; mainstream MS research treats MS as immune-mediated and has not adopted an infectious cause. The compilation they come from (the Grier summary below) is advocacy-adjacent; the individual papers carry the weight, and they are case-level.

Download: MS and Lyme research summary (PDF)

Testing: why "negative" isn't negative#

Lyme testing misses people.

• Strain variability: narrow antigen panels ignore the rest.
• Immune variability: not everyone mounts textbook antibodies.
• Gatekeeping: surveillance-grade criteria, applied as diagnostic cut-offs, exclude patients whose presentation does not fit.

Result: misdiagnosis, delay, damage, while the infection marches on.

When Standard Testing Fails: Diagnostic Alternatives#

The standard two-tier serology (ELISA + Western blot) is designed for surveillance, not diagnosis. Here's what frontline clinicians actually use when standard testing comes up empty:

Advanced Testing Options:

THE TIMING TRAP: By the time antibodies appear (weeks post-infection), Borrelia has already invaded protected niches. Early testing = false negative. Late testing = may miss dormant forms. The detection window is narrow on both ends.

CRITICAL DISTINCTION: CDC surveillance criteria are for epidemiological tracking, not individual patient care. Using surveillance case definitions as diagnostic gatekeeping is like using census data to decide whether an individual person exists.

Transmission: the map is bigger than ticks#

Ticks (Ixodes spp.) are the primary vector, but the story doesn't end there.

• Other arthropods: bed bugs, fleas, mites, lice have been implicated to varying degrees.
• Bodily fluids: Borrelia DNA/organisms detected in semen, blood, urine, saliva, yes, that puts sexual/contact transmission on the table.

Why it clusters in families#

• Genetic propensity: some people struggle to clear infections.
• Shared exposure: same house, same pests, same pets, same water, same risk.

Human-to-human?#

Lyme is treatable with antibiotics, and there's no sign of casual person-to-person spread during treatment.

Ticks Are Dirty Needles: The Co-Infection Reality#

Lyme disease is rarely a solo act. Ticks transmit multiple pathogens simultaneously; Borrelia is just the opening act*.

Common Co-Infections (What Else Is Hiding)#

Why this matters: Mono-therapy targeting only Borrelia often fails because:

• Different pathogens require different drugs
• Co-infections suppress immune function, enabling Borrelia persistence
• Symptoms overlap, masking which pathogens are active

RESEARCH WARNING: treating one pathogen in a polymicrobial illness is a recipe for failure. This is why ILADS physicians screen comprehensively, and why guideline focus on Borrelia alone leaves co-infections unaddressed when they are present.

THE BOTTOM LINE: When the vector transmits several pathogens, treating one does not cure the rest. Co-infection screening breadth is a clinical judgement call, and the guideline dispute is covered below.

The guideline dispute: IDSA vs ILADS#

The controversy over "chronic Lyme" is a scientific dispute with money on both sides of it.

IDSA vs ILADS: The Battle Lines#

Infectious Diseases Society of America (IDSA):

• Short-course antibiotics (10–28 days maximum)
• Persistent symptoms = "Post-Treatment Lyme Disease Syndrome" (PTLDS)
• View: Antibiotics always work; remaining symptoms are "post-infectious" damage or psychiatric

International Lyme and Associated Diseases Society (ILADS):

• Individualized, longer or repeated courses when infection is suspected
• Recognition that Borrelia can persist despite treatment
• View: Persistent infection is real and treatable

Regulators and insurers have largely sided with IDSA. Interests run in both directions, stated plainly:

• Short-course limits cut payer costs. Extended treatment is expensive, and payers benefit from narrow coverage.
• Extended treatment is also a revenue stream for the clinics that sell it. ILADS-aligned practice is not commerce-free.
• Guideline authorship has been formally scrutinised. The Connecticut attorney general's antitrust review of IDSA guideline development (2008) found no violation but required panel-process changes; the episode is cited by both sides in this argument.

PTLDS is a label, and the label is the argument. IDSA reads persistent symptoms as post-infectious damage or immune dysregulation; ILADS reads them as persisting infection. The words carry the conclusions. The trials that could separate the two readings are the retreatment RCTs, and they came back mixed to negative (Fallon 2008; Feder 2007).

THE PATTERN: The chronic-Lyme dispute ran the same sequence later seen in COVID-era medicine: patients psychiatrically labelled, treatment restricted by guideline, dissenting clinicians sanctioned. The sequence is documented in both eras. Whether it reflects coordinated intent or institutional self-protection is the part that stays contested.

Counter-evidence: what tests the hypothesis#

For people living with Lyme: calm the fire first (food → inflammation)#

The biochemical triggers of inflammation, and the foods that quietly feed the fire, informed by Wahls-style protocols and gut-immune research. Whether you're dealing with autoimmunity, neuroinflammation, chronic fatigue, IBD, MS, arthritis, or post-viral syndromes, removing inflammatory inputs is a power move.

1) Gluten-containing grains#

Gluten → zonulin → leaky gut; LPS translocation; molecular mimicry.

2) Dairy (esp. conventional A1 dairy)#

A1 casein → BCM-7 (gut/brain inflammation); lactase deficits; casein antibodies.

Later (if tolerated): A2 or fermented goat/sheep, exclude in elimination.

3) Legumes#

Lectins bind epithelium; phytates steal minerals; soy adds glyphosate/phytoestrogens; peanuts carry aflatoxins.

Pressure-cooking helps, doesn't erase all anti-nutrients, avoid early.

4) Nightshades (if sensitive)#

Alkaloids (solanine, capsaicin) can irritate gut, activate mast cells, and trigger neurogenic inflammation.

5) Processed sugars & refined carbs#

Glucose spikes → insulin surges → NF-κB/IL-6; dysbiosis; AGEs harm mitochondria, collagen, neurons.

6) Industrial seed oils#

High linoleic acid (ω-6) → pro-inflammatory eicosanoids; easy oxidation → lipid peroxides.

Swap: extra virgin olive oil, coconut oil, ghee, avocado oil, animal fats.

7) Trans fats#

Wreck membranes, insulin signaling, mitochondria.

Zero is the target.

8) Artificial additives & preservatives#

Mast-cell activation, histamine load; excitotoxins (MSG/aspartame) can worsen neuroinflammation; preservatives distort microbiota.

9) FODMAPs (for sensitive guts)#

Fermentable carbs can fuel IBS/SIBO; raise permeability and mast-cell activity.

Low-FODMAP is a tool, not a lifestyle, use briefly to calm the gut.

Simple swaps you can live with#

Polyphenol targets (food first)#

30–60 day reset (save this)#

• Eliminate: gluten, A1 dairy, legumes, seed oils, sugar, additives (trial nightshades/FODMAPs if symptomatic).
• Add: crucifers/sprouts, green tea, berries, EVOO, spices (turmeric).
• Track daily: sleep, pain (0–10), neuro sx, GI/stools, energy, HR/palps, foods.
• Reintroduce: one item every 3–4 days; note changes at 24/48/72 h.

Genome defense: antimutagens that matter#

High-heat meat makes heterocyclic aromatic amines (HAAs), genotoxic. Your counter-punch: crucifers (sulforaphane → GST), curcumin, resveratrol, chlorophyllin/green-tea polyphenols, and fiber to bind/excrete mutagens. That combo down-modulates CYP450 activation, shifts Phase II detox, controls ROS, and tunes gene expression.

• Review of 160+ studies on antimutagenic strategies: https://doi.org/10.1080/10408440091159176

Erich Traub and the biowarfare question, labelled allegation#

This section exists because the question keeps coming up. What is documented: Erich Traub was a real virologist with a Nazi-era research record who later worked with US institutions, and LCMV is a real neurotropic virus. What is alleged, in popular books rather than primary documents: a connection between that history, Plum Island, and the emergence of Lyme disease. This article carries no primary documentation for the allegation and does not treat it as fact. The pathogen biology stands on its own evidence without it.

Selected papers & reviews (quick links)#

Spirochetes in neurodegeneration / brain tissue

• Miklossy J. Alzheimer's disease, a neurospirochetosis. J Neuroinflammation (2011). https://doi.org/10.1186/1742-2094-8-90
• Riviere GR, et al. Oral Treponema in human brain associated with AD. J Alzheimers Dis (2002). https://doi.org/10.3233/jad-2002-4203
• MacDonald AB. Plaques of AD originate from cystic spirochetes. Med Hypotheses (2006). https://doi.org/10.1016/j.mehy.2006.02.035

Persistence / models

• Embers ME, et al. Borrelia persistence post-antibiotics in macaques. PLoS ONE (2012). https://doi.org/10.1371/journal.pone.0029914
• Sapi E, et al. Biofilm phenotype of Borrelia burgdorferi. Eur J Microbiol Immunol (2012). https://doi.org/10.1556/EuJMI.2.2012.4.4

Endothelial mechanics / transmigration

• Niddam AF, et al. Plasma fibronectin stabilizes Borrelia–endothelium catch-bonds under shear. PNAS (2017). https://doi.org/10.1073/pnas.1615007114

Cardiac involvement

• Yeung C, Baranchuk A. Diagnosis and Treatment of Lyme Carditis. J Am Coll Cardiol (2019). https://doi.org/10.1016/j.jacc.2018.11.035

Diagnostics

• Branda JA, et al. Two-tiered testing with C6 ELISA + immunoblot. Clin Infect Dis (2010). https://doi.org/10.1086/648674
• Fallon BA, et al. Repeated IV antibiotics for Lyme encephalopathy, RCT. Neurology (2008). https://doi.org/10.1212/01.WNL.0000284604.61160.2d

Food → barrier & inflammation

• Fasano A. Zonulin and intestinal barrier. Physiol Rev (2011). https://doi.org/10.1152/physrev.00003.2008
• A1 dairy → BCM-7
• Kamiński S, et al. β-casein polymorphism & health. J Appl Genet (2007). https://doi.org/10.1007/BF03195213
• Jinsmaa Y, Yoshikawa M. Enzymatic release of BCM-7. Peptides (1999). https://doi.org/10.1016/S0196-9781(99)00088-1

Lectins / antinutrients

• Pusztai A, Bardocz S (eds). Lectins: Biomedical Perspectives. CRC Press (1995). https://books.google.com/books/about/Lectins.html?id=qK40HAP6bGgC
• Liener IE. Antinutritional soybean components. Crit Rev Food Sci Nutr (1994). https://doi.org/10.1080/10408399409527653

Aflatoxins

• IARC Monographs, Aflatoxins. https://publications.iarc.fr/

Seed oils / linoleic acid

• Ramsden CE, et al. Dietary LA and CHD outcomes. BMJ (2013). https://doi.org/10.1136/bmj.e8707
• Kaur N, et al. Linoleic acid & inflammation. BBA (2014). https://doi.org/10.1016/j.bbalip.2014.04.001

Sugar → NF-κB / AGEs

• Brownlee M. The pathobiology of AGEs. Physiol Rev (2001). https://doi.org/10.1152/physrev.2001.81.1.1
• Devaraj S, et al. Glucose induces NF-κB activation. AJCN (2002). https://doi.org/10.1093/ajcn/75.1.2

Low-FODMAP (IBS tool)

• Halmos EP, et al. Low-FODMAP reduces IBS symptoms. Gastroenterology (2014). https://doi.org/10.1053/j.gastro.2013.09.046

Antimutagenic nutrition

• HAA antimutagen review (160+ studies). https://doi.org/10.1080/10408440091159176
• Polyphenols vs pancreatic cancer (pathways & CSCs). https://doi.org/10.3390/antiox9080651
• Diet & colorectal cancer (microbiome, epigenetics). https://doi.org/10.3390/nu13010143
• Annual Review of Nutrition (2008), Nutrition & Mutagenesis. https://doi.org/10.1146/annurev.nutr.28.061807.155449

Bottom line#

Borrelia detection in brain tissue is reported across a century of case literature; what it means for MS is unproven. Strip out what feeds inflammation, feed what protects your genome, and track your response with a clinician.

Reference correction, 11 October 2026. The lectins entry in the sources list cited "Pusztai A, Bardocz S. Plant Lectins. Taylor & Francis (1996)" with the DOI 10.1201/9781482295202, which is not registered at doi.org. No book with that title and authorship exists: Plant Lectins (1991, Cambridge University Press) is Pusztai's solo volume, and the book Pusztai and Bardocz edited together is Lectins: Biomedical Perspectives (CRC Press, 1995). The entry now cites the verified book with a working link. The article's claims are unchanged.

Educational content, not medical advice. Work with a clinician for diagnosis/treatment.